Wells Fargo Begins Coverage of Illumina with Outperform Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Wells Fargo Securities on Monday initiated coverage of Illumina with an Outperform rating, saying the company is "the clear market leader in next-generation sequencing, which we believe will be the primary tool enabling the application of personalized medicine."

The investment bank valued the San Diego-based company's shares in the $90 to $95 range and estimated its EPS for full-year 2013 at $1.72 on revenues of $1.38 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.